Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Cervical screening and HPV testing principles
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Screening must not delay assessment of symptoms
Heavy active bleeding, haemodynamic disturbance, severe pelvic pain, pregnancy-related bleeding or a cervix that looks malignant belongs to an urgent diagnostic pathway, not routine screening recall.
Action: Assess stability and pregnancy where relevant, examine with consent, control major bleeding, and use acute gynaecology or the suspected-cancer pathway according to the finding rather than waiting for an HPV screening result.
Role and principles
Apply England's current primary HPV screening pathway accurately while separating preventive screening from investigation of symptoms, visible cervical disease and specialist surveillance.
Primary HPV screening is a population prevention programme. Persistent infection with an oncogenic HPV type can cause transforming changes in cervical squamous or glandular epithelium over years. Most infections clear without treatment, so the programme does not send every HPV-positive person directly to excision. It combines HPV detection, reflex cytology, timed repeat testing and colposcopy to focus investigation on people whose persistence or cellular abnormality raises risk.
England changed routine recall prospectively on 1 July 2025. The call-and-recall service issues the first invitation at age 24.5. For people aged 25 to 64, a qualifying hrHPV-negative test taken on or after that date generally sets the next test at 5 years; dates already assigned were not retrospectively moved. A transitional exception applies under age 50 when an hrHPV-positive result occurred within the preceding 5 years: after a later negative result, recall is set at 3 years, and another negative result can then restore the 5-year interval. People who have never yet had primary HPV testing follow the due date already held until they attend.
Assessment and patient selection
Routine screening candidate
An asymptomatic person aged 25 to 64 with a cervix and no specialist surveillance requirement follows the national call-and-recall programme rather than opportunistic annual testing.
Primary HPV negative
No high-risk HPV is detected, cytology is not routinely processed, and the England programme usually assigns 5-year recall unless a defined transitional or surveillance exception applies.
Primary HPV positive
High-risk HPV is detected and reflex cervical cytology determines whether abnormal cells require immediate colposcopy or negative cytology permits timed HPV retesting.
Self-test limitation
A vaginal self-sample can establish HPV status for an eligible invited participant but cannot supply the cervical cytology needed to triage a positive result.
Diagnostic presentation
Bleeding, pain, abnormal discharge or a visibly suspicious cervix is assessed as a symptom or sign even if the person is below screening age or recently screened negative.
Red flags requiring action
A cervix with an irregular, ulcerated, friable or bleeding mass requires a suspected-cancer pathway referral regardless of age, vaccination or the last screening result.
Persistent postcoital or intermenstrual bleeding, blood-stained discharge, pelvic pain or unexplained weight loss requires diagnostic assessment even when screening is up to date.
Baseline assessment
01Clinician-taken primary hrHPV testFirst step
Why
Detect oncogenic HPV in a cervical liquid-based screening sample within the national programme.
Interpretation and limitations
A negative routine result usually leads to 5-year England recall; a positive result triggers reflex cytology rather than establishing cancer or requiring immediate treatment by itself.
02Reflex liquid-based cytology
Why
Identify cervical cellular abnormality in the same clinician-taken sample after hrHPV is detected.
Interpretation and limitations
Abnormal cytology prompts colposcopy; negative cytology enters the repeat HPV pathway, so it does not cancel the significance of persistent HPV.
03Programme HPV self-test
Why
Improve access for an eligible person specifically invited through England's phased self-testing route.
Interpretation and limitations
A negative result permits routine recall; after a positive result, a clinician-taken cervical sample repeats hrHPV and has reflex cytology only if that cervical sample remains positive.
04Speculum examination for symptoms
Why
Identify cervical, vaginal or vulval causes of bleeding or discharge outside preventive screening.
Interpretation and limitations
A suspicious cervical appearance overrides reassuring screening history and requires urgent referral and biopsy planning rather than repeat screening.
Interventions
01InvitationConfirm eligibility and support informed attendanceFirst stepA person receives an invitation, asks whether screening is due or has no reliable recall record.+
1Confirm that a cervix is present, identify the relevant UK national programme and retrieve the call-and-recall history rather than estimating from age alone.
2Explain primary HPV testing, possible reflex cytology and downstream outcomes, then address trauma, pain, disability, menopause, language and gender-related access needs.
3Arrange the programme-approved clinician sample or eligible invited self-test route and record consent, deferral or informed decline without removing future access.
02Laboratory resultFollow the linked HPV pathwayA primary screening or programme self-test result becomes available for action.+
1For a routine clinician-taken hrHPV-negative result, confirm the programme-calculated recall date, usually 5 years in England after the July 2025 change.
Targets, monitoring and follow-up
Document the exact HPV result, whether cytology was performed, the action code and the programme-generated next test due date rather than writing only 'smear normal'.
Use failsafe systems to confirm that positive self-tests receive clinician sampling and that cytology-abnormal or persistently HPV-positive results reach colposcopy.
Check completion after an unavailable or inadequate sample and avoid repeatedly resampling sooner than the programme's minimum interval.
At every later consultation, revisit new bleeding or discharge independently of the recall date and document the safety-net given.
Maintain accessible invitation options and review barriers after non-attendance without coercion, blame or assumptions about sexual activity.
Special situations
Five years is result based
England's interval extension follows a routine primary hrHPV-negative result; it does not convert every historical three-year recall or specialist surveillance episode automatically.
No cytology can be reassuring
When primary HPV is negative, absence of a cytology report is the designed laboratory pathway rather than evidence that the sample was forgotten.
Self-testing has a handoff
A positive vaginal self-test cannot supply cytology; safe implementation depends on a clinician cervical sample that repeats hrHPV before any indicated reflex cytology.
Vaccination does not erase anatomy
A vaccinated person with a cervix remains eligible because vaccine coverage is not universal across oncogenic types and previous exposure may have occurred.
Negative screening is not symptom clearance
Screening lowers population risk but is neither perfectly sensitive nor designed to identify every cervical, endometrial, vaginal or vulval cause of bleeding.
Common pitfalls
01
Repeating the old England three-year interval automatically for every hrHPV-negative person aged 25 to 49 after 1 July 2025.
02
Calling an HPV-positive result cervical cancer or implying that it identifies when or from whom infection was acquired.
03
Ordering cytology after every HPV-negative primary sample despite the programme's HPV-first laboratory design.
04
Using a self-test result as a substitute for examination when bleeding, pain, discharge or a visible cervical lesion is present.
05
Assuming a male or non-binary registration means there is no cervix or that an invitation will arrive automatically.
06
Ceasing recall at 65 without checking incomplete screening, previous treatment and any active surveillance protocol.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Applying the extended interval
An asymptomatic 32-year-old in England has a routine clinician-taken primary HPV screening result that is hrHPV negative and no HPV-positive result in the previous five years. When is routine recall due?
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Eligibility follows anatomy as well as registration. Anyone with a cervix in the screening age range is eligible, but a person not registered as female may not be included automatically and can ask to opt in. A total hysterectomy that removed the cervix changes eligibility, whereas subtotal hysterectomy leaves a cervix. Previous CIN, CGIN, cervical cancer, immunosuppression or incomplete screening near age 65 can create extended follow-up; never cease recall solely from age without checking the programme record.
A clinician-taken screening sample is collected from the cervix into liquid-based cytology medium. The laboratory performs a validated high-risk HPV assay first. If no hrHPV is detected, cytology is not routinely examined because the risk of significant cervical disease is low enough for recall. If hrHPV is detected, reflex cytology on the same cervical sample looks for abnormal cells. The report therefore needs to be read as a linked HPV-and-cytology pathway, not as two independent screening tests.
England began a phased, invitation-only HPV self-testing rollout on 25 August 2026, initially for underscreened or never-screened people aged 30 to 65 who had not attended after previous invitations. The vaginal sample detects hrHPV but supplies no cervical cells. A negative result returns an eligible participant to routine recall. After a positive self-test, take a clinician cervical sample and repeat hrHPV; perform reflex cytology only if that cervical sample remains positive. Repeat a first unavailable self-test with another kit, but use clinician sampling after a second unavailable result. Self-testing is not a requested home diagnostic test for symptoms.
Offer informed choice and make attendance practicable. Explain the speculum and brush, offer a chaperone, ask about pain, trauma, disability, menopause and gender-related concerns, and agree positioning or a smaller speculum where appropriate. Do not promise a painless test or proceed without consent. Defer routine screening in pregnancy until about 12 weeks after pregnancy ends, but do not defer colposcopy already indicated by an abnormal result or assessment of symptoms and a suspicious cervix.
Screening history modifies probability but never overrules symptoms. Postcoital bleeding, intermenstrual bleeding, persistent watery or blood-stained discharge and a suspicious cervix require history and examination. NICE recommends considering a suspected-cancer pathway referral when the cervix appears consistent with cancer. Taking a screening sample from a visibly abnormal cervix can delay the tissue diagnosis and must not replace urgent referral.
HPV vaccination and screening are complementary. Vaccination prevents infection from important vaccine HPV types most effectively before exposure, while screening detects current high-risk infection and its consequences. A vaccinated person can still acquire a non-vaccine oncogenic type or have infection acquired before vaccination. Conversely, an HPV-positive screening result does not prove recent transmission, partner infidelity or cancer and should be communicated without stigma.
Key points
Cervical screening is offered to asymptomatic women and people with a cervix to detect high-risk HPV and prevent cancer; it is not a diagnostic test for bleeding, pain or a visible lesion.
In England, the first invitation is sent at age 24.5 and routine screening covers ages 25 to 64; a routine primary hrHPV-negative result now sets a 5-year interval.
For qualifying tests taken on or after 1 July 2025, England uses a 5-year routine interval after hrHPV negativity; existing due dates were not moved retrospectively. Someone under 50 with hrHPV positivity in the preceding 5 years may receive a 3-year recall after a later negative result.
The laboratory tests the clinician-taken liquid-based sample for high-risk HPV first; cytology is performed only when hrHPV is detected, so an HPV-negative sample has no routine cytology report.
An hrHPV-positive result does not mean cancer. Reflex cytology separates immediate colposcopy referral from repeat HPV-based surveillance, while persistent infection drives escalation.
England began phased HPV self-testing on 25 August 2026 for invited underscreened or never-screened people aged 30 to 65 who had not attended after previous invitations; a kit cannot simply be requested outside that invitation route.
HPV vaccination greatly reduces risk but does not remove the need to accept screening invitations because vaccination does not prevent every oncogenic HPV infection or treat established infection.
Bleeding with hypotension, tachycardia, syncope, severe anaemia symptoms or pregnancy possibility needs same-day acute assessment before preventive care.
A person overdue after a previous abnormal result, treatment for CIN or cervical cancer may be on surveillance rather than routine recall and needs record reconciliation.
Immunosuppression, including HIV, can alter screening or surveillance arrangements and should prompt confirmation of the programme-specific plan.
05
Programme record review
Why
Confirm anatomy, prior results, treatment, recall date and whether routine screening, early recall or specialist surveillance applies.
Interpretation and limitations
The due date is determined by the complete pathway; age alone, a patient-recalled date or one isolated negative result can be misleading after previous HPV positivity or treatment.
2For hrHPV positivity on a cervical sample, use reflex cytology to determine colposcopy versus 12-month surveillance; for a positive self-test, arrange a clinician-taken sample first.
3Act on unavailable or inadequate results at the specified interval, and reconcile any previous positivity, CIN treatment or surveillance that changes routine recall.
03SymptomsLeave screening and investigate diseaseBleeding, abnormal discharge, pain or an abnormal cervical appearance is reported or found.+
1Assess bleeding severity, pregnancy possibility and pelvic symptoms, then offer a consented abdominal and genital examination appropriate to the presentation.
2Use acute care for instability and a suspected-cancer pathway for a cervix that appears malignant; do not wait for a screening invitation or HPV result.
3Investigate other causes according to age and findings, while separately correcting overdue preventive screening only when it will not delay diagnostic care.
Invitation and recall rules differ across England, Scotland, Wales and Northern Ireland; identify the national programme and follow the person's actual call-and-recall record.